Gastrointestinal STRING Test With Oral Immunotherapy
Trial ID or NCT#
Status
Purpose
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.
Official Title
Monitoring Gastrointestinal Responses In Food Oral Immunotherapy Using the Esophageal STRING Test
Eligibility Criteria
- • Participants, aged 5-55 years enrolled in the parent COMBINE trial - Able to swallow the EST.
- • Allergy to, or inability to ingest, gelatin -
Investigator(s)
View on ClinicalTrials.gov